{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:16:04Z","timestamp":1785453364100,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    The outcome of patients with acute myeloid leukemia (AML) worsens with increasing age. Dichotomization into \u201cyounger\u201d and \u201colder\u201d patients is clinically routine and often dictates treatment options. We aimed to delineate whether molecular genetic features and\/or outcome measures support assorting patient populations by age, including division into \u201cyounger\u201d and \u201colder\u201d groups. We analyzed 2823 adult AML patients enrolled onto frontline chemotherapy-based clinical protocols of two cooperative study groups from USA and Germany who were profiled molecularly via targeted sequencing platforms. Frequencies of gene mutations and cytogenetic findings were depicted in 5-year age increments. Clinical outcomes of 2756 AML patients were analyzed with respect to molecular features, genetic-risk groups and age. Age-associated distributions of gene mutations and cytogenetic abnormalities were similar in both cohorts. There was almost linear shortening of overall survival with increasing age among all patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001) and within 2022 European LeukemiaNet-defined genetic-risk groups, with survival decreasing as age increased (favorable-risk,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001; intermediate-risk,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001; adverse-risk,\n                    <jats:italic>P<\/jats:italic>\n                    \u2009&lt;\u20090.001). Although mutational profiles and outcomes of the youngest patients differed from those of older patients, there was no age cut-off identifying \u201cyounger\u201d and \u201colder\u201d patients. These findings support more age-associated flexibility for drug approval and trial eligibility.\n                  <\/jats:p>","DOI":"10.1038\/s41375-025-02644-0","type":"journal-article","created":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T16:20:10Z","timestamp":1758298810000},"page":"2926-2934","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Multi-dimensional analysis of adult acute myeloid leukemia cross-continents reveals age-associated trends in mutational landscape and treatment outcomes (Acute Myeloid Leukemia Cooperative Group &amp; Alliance for Clinical Trials in Oncology)"],"prefix":"10.1038","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4907-349X","authenticated-orcid":false,"given":"Monica","family":"Cusan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karilyn","family":"Larkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deedra","family":"Nicolet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vindi","family":"Jurinovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1408-5063","authenticated-orcid":false,"given":"Krzysztof","family":"Mr\u00f3zek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aarif M. N.","family":"Batcha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Rothenberg-Thurley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Sauerland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2574-9419","authenticated-orcid":false,"given":"Dennis","family":"G\u00f6rlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Utz","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang E.","family":"Berdel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2273-5502","authenticated-orcid":false,"given":"Bernhard J.","family":"Woermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Hiddemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6528-2078","authenticated-orcid":false,"given":"Jan","family":"Braess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5139-4957","authenticated-orcid":false,"given":"Karsten","family":"Spiekermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp A.","family":"Greif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4275-5562","authenticated-orcid":false,"given":"James S.","family":"Blachly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8971-2199","authenticated-orcid":false,"given":"Alice S.","family":"Mims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher C.","family":"Oakes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4537-1409","authenticated-orcid":false,"given":"Shelley","family":"Orwick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Blum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bayard L.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan E.","family":"Kolitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Mayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7526-2633","authenticated-orcid":false,"given":"Richard M.","family":"Stone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus H.","family":"Metzeler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9615-9432","authenticated-orcid":false,"given":"Tobias","family":"Herold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Kathrin","family":"Eisfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,19]]},"reference":[{"key":"2644_CR1","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1182\/blood-2002-03-0772","volume":"100","author":"JC Byrd","year":"2002","unstructured":"Byrd JC, Mr\u00f3zek K, Dodge RK, Carroll AJ, Edwards CG, Arthur DC, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood. 2002;100:4325\u201336.","journal-title":"Blood"},{"key":"2644_CR2","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1182\/blood-2009-11-254441","volume":"116","author":"D Grimwade","year":"2010","unstructured":"Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354\u201365.","journal-title":"Blood"},{"key":"2644_CR3","first-page":"16300","volume":"132","author":"K Mr\u00f3zek","year":"2022","unstructured":"Mr\u00f3zek K. Molecular cytogenetics in acute myeloid leukemia in adult patients: practical implications. Pol Arch Intern Med. 2022;132:16300.","journal-title":"Pol Arch Intern Med"},{"key":"2644_CR4","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Cancer Genome Atlas Research Network, Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, et al. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med. 2013;368:2059\u201374.","journal-title":"N Engl J Med"},{"key":"2644_CR5","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1182\/blood-2016-01-693879","volume":"128","author":"KH Metzeler","year":"2016","unstructured":"Metzeler KH, Herold T, Rothenberg-Thurley M, Amler S, Sauerland MC, G\u00f6rlich D, et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. 2016;128:686\u201398.","journal-title":"Blood"},{"key":"2644_CR6","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","volume":"374","author":"E Papaemmanuil","year":"2016","unstructured":"Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209\u201321.","journal-title":"N Engl J Med"},{"key":"2644_CR7","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.2022016867","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345\u201377.","journal-title":"Blood"},{"key":"2644_CR8","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1200\/JCO.2007.15.4245","volume":"27","author":"T B\u00fcchner","year":"2009","unstructured":"B\u00fcchner T, Berdel WE, Haferlach C, Haferlach T, Schnittger S, M\u00fcller-Tidow C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol. 2009;27:61\u20139.","journal-title":"J Clin Oncol"},{"key":"2644_CR9","first-page":"4173","volume":"58","author":"CD Bloomfield","year":"1998","unstructured":"Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R, et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res. 1998;58:4173\u20139.","journal-title":"Cancer Res"},{"key":"2644_CR10","doi-asserted-by":"crossref","DOI":"10.1007\/s11912-020-00964-1","volume":"22","author":"M Abdallah","year":"2020","unstructured":"Abdallah M, Xie Z, Ready A, Manogna D, Mendler JH, Loh KP. Management of acute myeloid leukemia (AML) in older patients. Curr Oncol Rep. 2020;22:103.","journal-title":"Curr Oncol Rep"},{"key":"2644_CR11","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","volume":"386","author":"P Montesinos","year":"2022","unstructured":"Montesinos P, Recher C, Vives S, Zarzycka E, Wang J, Bertani G, et al. Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia. N Engl J Med. 2022;386:1519\u201331.","journal-title":"N Engl J Med"},{"key":"2644_CR12","doi-asserted-by":"crossref","first-page":"3481","DOI":"10.1182\/blood-2005-09-3724","volume":"107","author":"FR Appelbaum","year":"2006","unstructured":"Appelbaum FR, Gundacker H, Head DR, Slovak ML, Willman CL, Godwin JE, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481\u20135.","journal-title":"Blood"},{"key":"2644_CR13","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.3324\/haematol.2019.245803","volume":"105","author":"ERM Scheepers","year":"2020","unstructured":"Scheepers ERM, Vondeling AM, Thielen N, van der Griend R, Stauder R, Hamaker ME. Geriatric assessment in older patients with a hematologic malignancy: a systematic review. Haematologica. 2020;105:1484\u201393.","journal-title":"Haematologica"},{"key":"2644_CR14","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood.2021013671","volume":"139","author":"G-J Min","year":"2022","unstructured":"Min G-J, Cho B-S, Park S-S, Park S, Jeon Y-W, Shin S-H, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139:1646\u201358.","journal-title":"Blood"},{"key":"2644_CR15","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1111\/j.1532-5415.2011.03614.x","volume":"59","author":"HD Klepin","year":"2011","unstructured":"Klepin HD, Geiger AM, Tooze JA, Kritchevsky SB, Williamson JD, Ellis LR, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc. 2011;59:1837\u201346.","journal-title":"J Am Geriatr Soc"},{"key":"2644_CR16","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","volume":"21","author":"SM Chan","year":"2015","unstructured":"Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, et al. Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med. 2015;21:178\u201384.","journal-title":"Nat Med"},{"key":"2644_CR17","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.beha.2013.10.003","volume":"26","author":"RL Levine","year":"2013","unstructured":"Levine RL. Molecular pathogenesis of AML: translating insights to the clinic. Best Pr Res Clin Haematol. 2013;26:245\u20138.","journal-title":"Best Pr Res Clin Haematol"},{"key":"2644_CR18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.blre.2014.07.002","volume":"29","author":"JP Sasine","year":"2015","unstructured":"Sasine JP, Schiller GJ. Emerging strategies for high-risk and relapsed\/refractory acute myeloid leukemia: novel agents and approaches currently in clinical trials. Blood Rev. 2015;29:1\u20139.","journal-title":"Blood Rev"},{"key":"2644_CR19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","volume":"133","author":"CD DiNardo","year":"2019","unstructured":"DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7\u201317.","journal-title":"Blood"},{"key":"2644_CR20","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","volume":"384","author":"EJ Duncavage","year":"2021","unstructured":"Duncavage EJ, Schroeder MC, O\u2019Laughlin M, Wilson R, MacMillan S, Bohannon A, et al. Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers. N Engl J Med. 2021;384:924\u201335.","journal-title":"N Engl J Med"},{"key":"2644_CR21","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2020001920","volume":"4","author":"MA Sekeres","year":"2020","unstructured":"Sekeres MA, Guyatt G, Abel G, Alibhai S, Altman JK, Buckstein R, et al. American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults. Blood Adv. 2020;4:3528\u201349.","journal-title":"Blood Adv"},{"key":"2644_CR22","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic\/dendritic neoplasms. Leukemia. 2022;36:1703\u201319.","journal-title":"Leukemia"},{"key":"2644_CR23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.12750","volume":"165","author":"R Liersch","year":"2014","unstructured":"Liersch R, M\u00fcller-Tidow C, Berdel WE, Krug U. Prognostic factors for acute myeloid leukaemia in adults-biological significance and clinical use. Br J Haematol. 2014;165:17\u201338.","journal-title":"Br J Haematol"},{"key":"2644_CR24","doi-asserted-by":"crossref","first-page":"2715","DOI":"10.1182\/blood.2020005498","volume":"136","author":"M Saad","year":"2020","unstructured":"Saad M, Loh KP, Tooze JA, Pardee TS, Ellis LR, Powell BL, et al. Geriatric assessment and survival among older adults receiving postremission therapy for acute myeloid leukemia. Blood. 2020;136:2715\u20139.","journal-title":"Blood"},{"key":"2644_CR25","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1038\/s41375-018-0068-2","volume":"32","author":"A-K Eisfeld","year":"2018","unstructured":"Eisfeld A-K, Kohlschmidt J, Mr\u00f3zek K, Blachly JS, Walker CJ, Nicolet D, et al. Mutation patterns identify adult patients with de novo acute myeloid leukemia aged 60 years or older who respond favorably to standard chemotherapy: an analysis of Alliance studies. Leukemia. 2018;32:1338\u201348.","journal-title":"Leukemia"},{"key":"2644_CR26","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1038\/s41375-020-0872-3","volume":"34","author":"AK Eisfeld","year":"2020","unstructured":"Eisfeld AK, Kohlschmidt J, Mims A, Nicolet D, Walker CJ, Blachly JS, et al. Additional gene mutations may refine the 2017 European LeukemiaNet classification in adult patients with de novo acute myeloid leukemia aged\u2009<60 years. Leukemia. 2020;34:3215\u201327.","journal-title":"Leukemia"},{"key":"2644_CR27","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1038\/s41375-020-0806-0","volume":"34","author":"T Herold","year":"2020","unstructured":"Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, et al. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020;34:3161\u201372.","journal-title":"Leukemia"},{"key":"2644_CR28","doi-asserted-by":"crossref","first-page":"308","DOI":"10.3324\/haematol.2013.092072","volume":"99","author":"M Wetzler","year":"2014","unstructured":"Wetzler M, Mr\u00f3zek K, Kohlschmidt J, Dombret H, D\u00f6hner H, Pilorge S, et al. Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification. Haematologica. 2014;99:308\u201313.","journal-title":"Haematologica"},{"key":"2644_CR29","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.3324\/haematol.2018.191536","volume":"103","author":"VV Prassek","year":"2018","unstructured":"Prassek VV, Rothenberg-Thurley M, Sauerland MC, Herold T, Janke H, Ksienzyk B, et al. Genetics of acute myeloid leukemia in the elderly: mutation spectrum and clinical impact in intensively treated patients aged 75 years or older. Haematologica. 2018;103:1853\u201361.","journal-title":"Haematologica"},{"key":"2644_CR30","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.3324\/haematol.2012.064667","volume":"97","author":"PA Greif","year":"2012","unstructured":"Greif PA, Konstandin NP, Metzeler KH, Herold T, Pasalic Z, Ksienzyk B, et al. RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. Haematologica. 2012;97:1909\u201315.","journal-title":"Haematologica"},{"key":"2644_CR31","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.2011.40.6652","volume":"30","author":"JH Mendler","year":"2012","unstructured":"Mendler JH, Maharry K, Radmacher MD, Mr\u00f3zek K, Becker H, Metzeler KH, et al. RUNX1 mutations are associated with poor outcome in younger and older patients with cytogenetically normal acute myeloid leukemia and with distinct gene and microRNA expression signatures. J Clin Oncol. 2012;30:3109\u201318.","journal-title":"J Clin Oncol"},{"key":"2644_CR32","volume":"10","author":"SP Tsui","year":"2020","unstructured":"Tsui SP, Ip HW, Saw NY, Zhang C, Cheung AK, Ng NK, et al. Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults. Blood Cancer J. 2020;10:104.","journal-title":"Blood Cancer J"},{"key":"2644_CR33","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1093\/jnci\/djab070","volume":"113","author":"D Habr","year":"2021","unstructured":"Habr D, McRoy L, Papadimitrakopoulou VA. Age is just a number: considerations for older adults in cancer clinical trials. J Natl Cancer Inst. 2021;113:1460\u20134.","journal-title":"J Natl Cancer Inst"},{"key":"2644_CR34","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood-2009-07-229492","volume":"116","author":"JE Kolitz","year":"2010","unstructured":"Kolitz JE, George SL, Marcucci G, Vij R, Powell BL, Allen SL, et al. P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients under age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808. Blood. 2010;116:1413\u201321.","journal-title":"Blood"},{"key":"2644_CR35","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/leu.2016.252","volume":"31","author":"W Blum","year":"2017","unstructured":"Blum W, Sanford BL, Klisovic R, DeAngelo DJ, Uy G, Powell BL, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission: a phase 2 Cancer and Leukemia Group B study (CALGB 10503). Leukemia. 2017;31:34\u20139.","journal-title":"Leukemia"},{"key":"2644_CR36","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1200\/JCO.2008.17.0472","volume":"26","author":"MR Baer","year":"2008","unstructured":"Baer MR, George SL, Caligiuri MA, Sanford BL, Bothun SM, Mr\u00f3zek K, et al. Low-dose interleukin-2 immunotherapy does not improve outcome of patients age 60 years and older with acute myeloid leukemia in first complete remission: Cancer and Leukemia Group B study 9720. J Clin Oncol. 2008;26:4934\u20139.","journal-title":"J Clin Oncol"},{"key":"2644_CR37","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1200\/JCO.2004.11.106","volume":"22","author":"JE Kolitz","year":"2004","unstructured":"Kolitz JE, George SL, Dodge RK, Hurd DD, Powell BL, Allen SL, et al. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B study 9621. J Clin Oncol. 2004;22:4290\u2013301.","journal-title":"J Clin Oncol"},{"key":"2644_CR38","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1182\/bloodadvances.2021004233","volume":"5","author":"AR Walker","year":"2021","unstructured":"Walker AR, Marcucci G, Yin J, Blum W, Stock W, Kohlschmidt J, et al. Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv. 2021;5:2775\u201387.","journal-title":"Blood Adv"},{"key":"2644_CR39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJM199410063311402","volume":"331","author":"RJ Mayer","year":"1994","unstructured":"Mayer RJ, Davis RB, Schiffer CA, Berg DT, Powell BL, Schulman P, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. N Engl J Med. 1994;331:896\u2013903.","journal-title":"N Engl J Med"},{"key":"2644_CR40","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1182\/blood-2004-08-2977","volume":"105","author":"JO Moore","year":"2005","unstructured":"Moore JO, George SL, Dodge RK, Amrein PC, Powell BL, Kolitz JE, et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B study 9222. Blood. 2005;105:3420\u20137.","journal-title":"Blood"},{"key":"2644_CR41","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454\u201364.","journal-title":"N Engl J Med"},{"key":"2644_CR42","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1182\/bloodadvances.2018023689","volume":"2","author":"GJ Roboz","year":"2018","unstructured":"Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, et al. A randomized trial of 10 days of decitabine alone or with bortezomib in previously untreated older patients with acute myeloid leukemia: CALGB 11002 (Alliance). Blood Adv. 2018;2:3608\u201317.","journal-title":"Blood Adv"},{"key":"2644_CR43","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1200\/JCO.2012.45.2177","volume":"31","author":"EC Attar","year":"2013","unstructured":"Attar EC, Johnson JL, Amrein PC, Lozanski G, Wadleigh M, DeAngelo DJ, et al. Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502. J Clin Oncol. 2013;31:923\u20139.","journal-title":"J Clin Oncol"},{"key":"2644_CR44","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJM199506223322503","volume":"332","author":"RM Stone","year":"1995","unstructured":"Stone RM, Berg DT, George SL, Dodge RK, Paciucci PA, Schulman P, et al. Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. N Engl J Med. 1995;332:1671\u20137.","journal-title":"N Engl J Med"},{"key":"2644_CR45","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1200\/JCO.1999.17.9.2831","volume":"17","author":"EJ Lee","year":"1999","unstructured":"Lee EJ, George SL, Caligiuri M, Szatrowski TP, Powell BL, Lemke S, et al. Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: Results of Cancer and Leukemia Group B study 9420. J Clin Oncol. 1999;17:2831\u20139.","journal-title":"J Clin Oncol"},{"key":"2644_CR46","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1182\/bloodadvances.2016003053","volume":"1","author":"GL Uy","year":"2017","unstructured":"Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Adv. 2017;1:331\u201340.","journal-title":"Blood Adv"},{"key":"2644_CR47","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1182\/blood.V89.3.780","volume":"89","author":"JO Moore","year":"1997","unstructured":"Moore JO, Dodge RK, Amrein PC, Kolitz J, Lee EJ, Powell B, et al. Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and Leukemia Group B study 9022. Blood. 1997;89:780\u20138.","journal-title":"Blood"},{"key":"2644_CR48","first-page":"460","volume":"78","author":"CA Schiffer","year":"1991","unstructured":"Schiffer CA, Davis RB, Schulman P, Cooper B, Coyle T, Lee E, et al. Intensive post remission therapy of acute myeloid leukemia (AML) with cytoxan\/etoposide (CY\/VP16) and diazaquone\/mitoxantrone (AZQ\/MITO). Blood. 1991;78:460.","journal-title":"Blood"},{"key":"2644_CR49","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1200\/JCO.2012.42.2907","volume":"30","author":"T B\u00fcchner","year":"2012","unstructured":"B\u00fcchner T, Schlenk RF, Schaich M, D\u00f6hner K, Krahl R, Krauter J, et al. Acute Myeloid Leukemia (AML): different treatment strategies versus a common standard arm- combined prospective analysis by the German AML Intergroup. J Clin Oncol. 2012;30:3604\u201310.","journal-title":"J Clin Oncol"},{"key":"2644_CR50","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1038\/s41375-018-0268-9","volume":"32","author":"J Braess","year":"2018","unstructured":"Braess J, Amler S, Kreuzer K-A, Spiekermann K, Lindemann HW, Lengfelder E, et al. Sequential high-dose cytarabine and mitoxantrone (S-HAM) versus standard double induction in acute myeloid leukemia-a phase 3 study. Leukemia. 2018;32:2558\u201371.","journal-title":"Leukemia"},{"key":"2644_CR51","first-page":"239","volume":"33","author":"K Mr\u00f3zek","year":"2008","unstructured":"Mr\u00f3zek K, Carroll AJ, Maharry K, Rao KW, Patil SR, Pettenati MJ, et al. Central review of cytogenetics is necessary for cooperative group correlative and clinical studies of adult acute leukemia: the Cancer and Leukemia Group B experience. Int J Oncol. 2008;33:239\u201344.","journal-title":"Int J Oncol"},{"key":"2644_CR52","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1038\/leu.2017.86","volume":"31","author":"A-K Eisfeld","year":"2017","unstructured":"Eisfeld A-K, Mr\u00f3zek K, Kohlschmidt J, Nicolet D, Orwick S, Walker CJ, et al. The mutational oncoprint of recurrent cytogenetic abnormalities in adult patients with de novo acute myeloid leukemia. Leukemia. 2017;31:2211\u20138.","journal-title":"Leukemia"},{"key":"2644_CR53","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1038\/leu.2017.109","volume":"31","author":"P Silva","year":"2017","unstructured":"Silva P, Neumann M, Schroeder MP, Vosberg S, Schlee C, Isaakidis K, et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia. 2017;31:1640\u20134.","journal-title":"Leukemia"},{"key":"2644_CR54","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","volume":"28","author":"G Marcucci","year":"2010","unstructured":"Marcucci G, Maharry K, Wu Y-Z, Radmacher MD, Mr\u00f3zek K, Margeson D, et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol. 2010;28:2348\u201355.","journal-title":"J Clin Oncol"},{"key":"2644_CR55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.jgo.2019.11.001","volume":"11","author":"EB Ludmir","year":"2020","unstructured":"Ludmir EB, Subbiah IM, Mainwaring W, Miller AB, Lin TA, Jethanandani A, et al. Decreasing incidence of upper age restriction enrollment criteria among cancer clinical trials. J Geriatr Oncol. 2020;11:451\u20134.","journal-title":"J Geriatr Oncol"},{"key":"2644_CR56","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1001\/jamaoncol.2019.2055","volume":"5","author":"EB Ludmir","year":"2019","unstructured":"Ludmir EB, Mainwaring W, Lin TA, Miller AB, Jethanandani A, Espinoza AF, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol. 2019;5:1769\u201373.","journal-title":"JAMA Oncol"},{"key":"2644_CR57","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","volume":"378","author":"CD DiNardo","year":"2018","unstructured":"DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, et al. Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML. N Engl J Med. 2018;378:2386\u201398.","journal-title":"N Engl J Med"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02644-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02644-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T09:10:25Z","timestamp":1763629825000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-025-02644-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":57,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2644"],"URL":"https:\/\/doi.org\/10.1038\/s41375-025-02644-0","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"28 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 April 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were conducted in accordance with relevant guidelines and regulations. All study protocols were approved by the Institutional Review Boards of participating centers in accordance with the Declaration of Helsinki. All patients provided written informed consent for inclusion on the clinical trial and genetic analyses. Cancer Therapy Evaluation Program approval was obtained on\u00a0September 13, 2024. Additional details are provided in the Supplementary Information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}